CTLA4 and neoplasm: As a co-inhibitory receptor, CTLA-4 on Tregs inhibits co-stimulatory signaling through higher affinity binding to CD80/86 on APC compared with the co-stimulatory receptor CD28 on T cells, resulting in the impairment of the antitumor immune response and acceleration of immune evasion of tumor cells (41).